Regulatory

Navigating the Global Regulatory Matrix: A Strategic Guide to FDA, EMA, MHRA, PMDA, and NMPA Meetings for Biotech Founders

Leave a Comment / Regulatory /

Global Regulatory Engagement Series This executive series provides startup and midsize biotech leaders with actionable, cross-functional blueprints for engaging global regulatory authorities (FDA, EMA, MHRA, PMDA, NMPA) across preclinical, translational, and clinical drug development. Article Sequence Thematic Focus Status Article 1 (Current) Navigating the Global Regulatory Matrix: A Strategic Guide to FDA, EMA, MHRA, PMDA, […]

Navigating the Global Regulatory Matrix: A Strategic Guide to FDA, EMA, MHRA, PMDA, and NMPA Meetings for Biotech Founders Read More »

The MIE Shift: When the Model Becomes the Primary Evidence for FDA Approval

Clinical Pharmacology, Drug Development Strategy, Regulatory /

Executive Summary For a long time, the pharmaceutical industry viewed Clinical Pharmacology models as helpful supporting characters. They were tools used to guide a trial design or help justify a specific dose. As we move through 2026, a fundamental shift has taken place. The FDA and EMA have moved from Model Informed to Model Integrated

The MIE Shift: When the Model Becomes the Primary Evidence for FDA Approval Read More »